Soligenix (SNGX) Registration Filing summary

Company overview and business model

• Operates as a late-stage biopharmaceutical company focused on rare diseases with unmet medical needs, with two business segments: Specialized BioTherapeutics and Public Health Solutions.

• Specialized BioTherapeutics is advancing HyBryte™ (synthetic hypericin sodium) for cutaneous T-cell lymphoma (CTCL), with a second Phase 3 trial underway and top-line results expected in the second half of 2026.

• Additional pipeline includes SGX302 for psoriasis, SGX942 for oral mucositis, and SGX945 for Behçet's Disease, as well as vaccine candidates for ricin, filoviruses, and COVID-19 using proprietary ThermoVax® technology.

• Public Health Solutions segment is primarily funded by government grants and contracts.

Financial performance and metrics

• Reported net loss of $8.3 million for the year ended December 31, 2024, compared to $6.1 million in the prior year, driven by increased R&D expenses and lower grant revenue.

• As of June 30, 2025, cash and cash equivalents were $5.1 million, with working capital of $1.7 million, and an accumulated deficit of $239.6 million.

• Research and development expenses for the six months ended June 30, 2025, were $3.6 million, up from $1.6 million in the prior year period.

• Revenues are primarily from government grants, with $119,371 recognized in 2024, down from $839,359 in 2023.

• Auditor's report includes a going concern qualification due to recurring losses and negative cash flows.

Use of proceeds and capital allocation

• Net proceeds from the offering (estimated at $7.3 million at $2.75 per share) will fund R&D and commercialization activities, general corporate purposes, working capital, product development, acquisitions, capital expenditures, and debt repayment.

• Management retains broad discretion over allocation of proceeds.